These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6181745)

  • 1. [Prolactin and prostate cancer. II. Blood levels of prolactin in prostatic tumors].
    Maganto Pavón E; Mayayo Dehesa T; Mateos Torres JA; Verdú Tartajo F; de Blas Gómez V; Romero Aguirre C
    Arch Esp Urol; 1982; 35(3):171-8. PubMed ID: 6181745
    [No Abstract]   [Full Text] [Related]  

  • 2. [Increased secretion of prolactin after inhibition of dopaminergic receptors by metoclopramide in patients with cancer of the prostate].
    Baranowska B; Jeske W; Szymanowski J; Piechna K
    J Urol (Paris); 1983; 89(8):601-5. PubMed ID: 6203986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
    Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
    Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of ergobromocriptine on serum testosterone and prolactin levels in patients with carcinoma of the prostate.
    Taşar C; Akdaş A; Kirkali Z
    Int Urol Nephrol; 1986; 18(1):71-4. PubMed ID: 2424860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurements of prolactin and androgens in patients with prostatic disease.
    Saroff J; Kirdani RY; Chu TM; Wajsman Z; Murphy GP
    Surg Forum; 1977; 28():568-9. PubMed ID: 83009
    [No Abstract]   [Full Text] [Related]  

  • 6. [Present-day possibilities of prostate cancer screening in patients with benign prostatic hyperplasia before and after surgical treatment].
    Pushkar' DIu; Rasner PI; Skobelev PP
    Urologiia; 2001; (6):48-54. PubMed ID: 11785083
    [No Abstract]   [Full Text] [Related]  

  • 7. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The prognostic significance of prolactin in prostate cancer].
    Røhl HF; Andersen OP
    Ugeskr Laeger; 1987 Dec; 149(50):3402-3. PubMed ID: 3433541
    [No Abstract]   [Full Text] [Related]  

  • 9. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Morphological and hormonal diagnosis of prostate cancer].
    Minkov N; Kumanov Kh; Tsvetkov M; Topov Ia; Maleeva A
    Khirurgiia (Sofiia); 1983; 36(3):249-51. PubMed ID: 6198553
    [No Abstract]   [Full Text] [Related]  

  • 11. Prolactin and prostate: a chronobiologic study.
    Selli C; Benvenuti M; Melone F; Romano S; Tarquini B
    Eur Urol; 1983; 9(2):109-12. PubMed ID: 6189717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Activity of protein C in blood of patients with prostatic carcinoma].
    Iwan-Zietek I; Zietek Z; Kotschy M; Tyloch F; Zastawna E
    Pol Tyg Lek; 1996 Feb; 51(6-9):94-5. PubMed ID: 8756742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level.
    Punglia RS; D'Amico AV; Catalona WJ; Roehl KA; Kuntz KM
    Cancer; 2006 Apr; 106(7):1507-13. PubMed ID: 16518812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased serum prolactin pituitary reserve in patients with prostatic neoplasms.
    Giuliani L; Pescatore D; Martorana G; Giberti C; Barreca T; Rolandi E
    Br J Urol; 1979 Oct; 51(5):390-2. PubMed ID: 93008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baldness, benign prostate hyperplasia, prostate cancer and androgen levels.
    Faydaci G; Bilal E; Necmettin P; Fatih T; Asuman O; Uğur K
    Aging Male; 2008 Dec; 11(4):189-92. PubMed ID: 19172550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Activity of alpha 1-antitrypsin in blood of patients with prostatic tumor].
    Zietek Z; Iwan-Zietek I; Kotschy M; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):89-90. PubMed ID: 8756740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early detection of prostatic carcinoma: Is PSA screening suitable?].
    Kaulen H
    Dtsch Med Wochenschr; 2003 May; 128(18):977. PubMed ID: 12755136
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prognostic value of serum prolactin in the treatment of prostatic cancer].
    Maganto E; Jiménez M; Burgos J; Escribano G; Allona A; Escudero A
    Actas Urol Esp; 1986; 10(6):441-4. PubMed ID: 3825645
    [No Abstract]   [Full Text] [Related]  

  • 20. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
    Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
    Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.